EFAVIRENZ, LAMIVUDINE, AND TENOFOVIR DISOPROXIL FUMARATE

Pre-Launch

NDAORALTABLET

Lifecycle

Pre-Launch

Data completeness

1/8 — Limited

EFAVIRENZ, LAMIVUDINE, AND TENOFOVIR DISOPROXIL FUMARATE by Cipla is fixed-dose combination of antiviral drugs efv, 3tc, and tdf with antiviral activity against hiv-1 [see ].

Drug data last refreshed 20h ago · AI intelligence enriched 2w ago

AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data

This is a fixed-dose combination tablet containing efavirenz, lamivudine, and tenofovir disoproxil fumarate—three antiviral agents combined to treat HIV-1 infection. The combination leverages complementary mechanisms of action: efavirenz is a non-nucleoside reverse transcriptase inhibitor, while lamivudine and tenofovir are nucleoside/nucleotide reverse transcriptase inhibitors. This product targets treatment-naïve and treatment-experienced patients seeking simplified, single-tablet regimens.

PRE_LAUNCH

Pre-launch stage indicates active role-building across commercial, medical affairs, and regulatory teams; career growth tied to successful market entry and adoption in developed and emerging markets.

Mechanism of Action

fixed-dose combination of antiviral drugs EFV, 3TC, and TDF with antiviral activity against HIV-1 [see ].

Indications

Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.

Career Relevance

Working on this pre-launch product offers career exposure to global HIV market dynamics, emerging market strategy, and government pricing negotiations—skills highly valued in pharma. The role involves building brand infrastructure from ground zero, making it ideal for professionals seeking high-impact, visible contributions.

Brand ManagerMedical Science Liaison

Worked on EFAVIRENZ, LAMIVUDINE, AND TENOFOVIR DISOPROXIL FUMARATE at Cipla? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.